NasdaqGS:INDVPharmaceuticals
Assessing Indivior Pharmaceuticals (NasdaqGS:INDV) Valuation After New SUBLOCADE Cost Savings Evidence In Corrections Settings
Indivior Pharmaceuticals (INDV) is back in focus after a new peer reviewed cost impact model suggested its monthly SUBLOCADE injection could reduce staff time and operational costs for treating opioid use disorder in correctional facilities.
See our latest analysis for Indivior Pharmaceuticals.
The new cost impact data lands after a volatile stretch for the stock, with the share price at US$30.47 and a 1 year total shareholder return of 224.84% alongside a 74.61% 3 year total shareholder...